Back
Amedisys Quote, Financials, Valuation and Earnings
Sponsored
AMED
Sponsored
Trump's Legacy-Defining Momentor Strike
But the Surprising Way Trump Solves it Could Cement His Legacy.
Sell
47
AMED
Amedisys
Last Price:
$84.56
Seasonality Move:
8.5%
7 Day Trial
ALL ACCESS PASS
$
7
Elon Musk Predicts MAJOR Crisis in Trump's First Year
See Why Investors are Pouring Mountains of Cash into Certain Companies Trump Wants to Solve the Problem.Amedisys Price Quote
$84.56
+0.07 (+0.93%)
(Updated: December 21, 2024 at 5:14 AM ET)
Amedisys Key Stats
Sell
47
Amedisys (AMED)
is a Sell
Day range:
$82.15 - $84.87
52-week range:
$82.15 - $98.95
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.20
P/B ratio:
2.41%
Volume:
2.3M
Avg. volume:
720.6K
1-year change:
-11.09%
Market cap:
$2.8B
Revenue:
$2.2B
EPS:
$2.52
How Much Does Amedisys Make?
Data Unavailable
Is Amedisys Growing As A Company?
Data Unavailable
Amedisys Stock Price Performance
What Is Amedisys 52-Week High & Low?
Amedisys Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Amedisys?
Data Unavailable
Is Amedisys Cash Flow Positive?
Data Unavailable
Amedisys Return On Invested Capital
Data Unavailable
Amedisys Earnings Date & Stock Price
-
What Is Amedisys's Stock Price Today?A single share of AMED can be purchased today for 84.49
-
What Is Amedisys’s Stock Symbol?
-
When Is Amedisys’s Next Earnings Date?The next quarterly earnings date for Amedisys is scheduled on February 21, 2025
-
When Is AMED's next ex-dividend date?Amedisys's next ex-dividend date is December 22, 2024
-
How To Buy Amedisys Stock?You can buy Amedisys shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Amedisys Competitors
Amedisys Dividend Yield
Data Unavailable
Amedisys Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | -35.44% | -14.33% |
Revenue: | 5.65% | -0.19% |
Analyst Recommendations
Buy Recommendations: | 0 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 0.00 |
Downside from Last Price: | -100% |
Major Shareholders
Data Unavailable